Navigation Links
Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
Date:10/4/2011

SAN DIEGO, Oct. 4, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the launch of its iPLEX ADME PGx panel developed to genotype polymorphisms in genes associated with drug absorption, distribution, metabolism, and excretion (ADME). This Research Use Only (RUO) panel contains a set of pre-designed single nucleotide polymorphisms (SNP), insertions and deletions (INDELS) and copy number variation (CNV) assays for use in the investigation of variants with demonstrated relevance to drug metabolism. After detection on the MassARRAY (RUO) system, the proprietary software solution is then used to score and qualify polymorphisms to create a unique haplotype report.

"Sequenom customers have been successful in developing assays for a wide variety of ADME biomarkers, and numerous high-impact studies have been published using Sequenom technology," said Michael Monko, Senior Vice President, Genetic Analysis. "The iPLEX ADME PGx panel should help scientists quickly and reliably screen samples for genotypes relevant to drug metabolism, speeding the discovery of relevant genotypic markers associated with specific drug treatments."

The iPLEX ADME PGx panel should enable the basic and translational research communities to rapidly and accurately investigate pharmacogenetic biomarkers associated with drug metabolism. The iPLEX ADME PGx panel enables the analysis of 192 polymorphisms across 36 pharmacogenetically relevant genes. The panel uses Sequenom's iPLEX Gold biochemistry together with specific ADME oligonucleotides. The PGx panel consists of 200 assays in 8 wells requiring 10 ng of input DNA per well from fresh or frozen whole blood or cells.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements  

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the anticipated use, performance and benefits of the iPLEX ADME PGx panel and its acceptance and use as a genotyping tool by basic and translational researchers for pharmacogenetic applications, and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the iPLEX ADME PGx panel, the Company's ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms and panels, reliance upon the collaborative efforts of other parties, ongoing litigation involving the Company, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. SEQUENOM Announces Launch of MassARRAY Compact 96 System
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. Sequenom Appoints Two New Board Members
6. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom to Present at Two Financial Conferences in September
9. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Financial Highlights ... unaudited)Three Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$   ... Product Revenue 3539(10)%9498(4)%Kuvan Net Product ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), ... medical conditions, today announced that Linda Marbán, Ph.D, president and ... investor conferences: Cowen and Company 37th ... am ET Boston, MA ... 9:00 am PT (12:00 pm ET) Dana Point, ...
Breaking Biology Technology:
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):